Pharmaceutical

Avalyn raises $175m in funding to develop inhaled IPF drugs

The funding was part of an oversubscribed Series C financing that will be used to advance its lead IPF therapies into Phase II trials.

Sep 27, 2023 - 20:00
Avalyn raises $175m in funding to develop inhaled IPF drugs
The funding was part of an oversubscribed Series C financing that will be used to advance its lead IPF therapies into Phase II trials.
Read the original article

Tags:

Previous Article

Glenmark to market Winlevi in Europe and South Africa after Cosmo deal

Next Article

Galecto downsizes by 70% following Phase II trial failure

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Here are the dozens of weight loss drugs in development to catch a booming market

STAT+: Here are the dozens of weight loss drugs in deve...

Sep 12, 2023

What makes a drug a blockbuster — or a cautionary tale?

What makes a drug a blockbuster — or a cautionary tale?

Feb 3, 2024

Opinion: After living with sickle cell disease for 39 years, I’m both excited and skeptical about the newly approved gene therapies

Opinion: After living with sickle cell disease for 39 y...

Dec 9, 2023